Majun-e-Suranjan and Habb-e-Azraqi are two Unani compound drugs that are effective and safe in cases of gout - An initial study
Abstract
Present study evaluated the therapeutic efficacy and safety of two Unani compound drugs Majun-e-Suranjan and Habb-e-Azraqi in cases of gout on modern scientific parameters viz., clinical, biochemical and haematological. This work was conducted at Regional Research Institute of Unani Medicine (RRIUM), Aligarh, during 2014-2019. 71 people were chosen from the pool of patients visiting the outpatient department (OPD). Patients received the Unani medicines Majun-e-Suranjan in a dose of 5.0 g and Habb-e-Azraqi in a dose of 1 pill (250 mg) twice daily after meals for a period of 56-days. One-way analysis of variance (ANOVA) was used for the analysis of data, and the statistical significance of the findings was determined by Dennett's test. The study reveals that the two Unani medicines are safe, non-toxic, and significantly relieve the symptoms of gouty arthritis. It is suggested to conduct more research among a large population.
Keyword(s)
Gout, Unani compound drugs (Majun-e-Suranjan, Habb-e-Azraqi), efficacy and safety
Full Text: PDF (downloaded 573 times)
Refbacks
- There are currently no refbacks.